OLIVIA BURCH: Open Payments
NPI 1982247888 · MAGEE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,631 in 84 payments from 19 companies in 2025. Trend: 2023 $124 · 2024 $24 · 2025 $1,631
Food & beverage: $1,631
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 15 | $226 |
| Bayer Healthcare Pharmaceuticals Inc. | 10 | $224 |
| Lilly USA, LLC | 10 | $177 |
| Novo Nordisk Inc | 10 | $161 |
| Xeris Pharmaceuticals, Inc. | 7 | $142 |
| Astellas Pharma US Inc | 2 | $138 |
| Tandem Diabetes Care, Inc. | 8 | $122 |
| AstraZeneca Pharmaceuticals LP | 6 | $97 |
| Esperion Therapeutics, Inc. | 4 | $62 |
| Stryker Corporation | 1 | $55 |
Products named: Korlym, Kerendia, MOUNJARO, RECORLEV, Veozah, t:slim X2 Insulin Pump with Control-IQ, FARXIGA, Ozempic.
Industry payments across MS — which companies pay providers there.
